ClinicalTrials.gg
RecruitingNCT06340620Updated Oct 20, 2026

EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope

An interventional study of Endoscopic ultrasound examination in Pancreatic Disease, Pancreatic Cancer and Pancreatic Cyst, sponsored by Orlando Health, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Orlando Health, Inc. · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 20, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Pancreatic Diseases with a site in United States — 13 open to participants now, 15 under way, 1 of them phase 3. Pancreatic Diseases · United States.

Planned enrollment
12th of 42
140 · median 76
Started
2026
with 1 other
No phase
13 of 60
2 open now
Primary completion
2027-12
later than 10 of 14 live
Registered
54th of 60
by date
Lead sponsor
2 of 60
Orlando Health, Inc.

Among the 60 studies in Pancreatic Diseases with a site in United States, this one is the 12th largest by planned enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2026, is one of 13 with no phase, reaches primary completion later than 10 of the 14 other live ones, and was the 54th registered.

Pancreatic Diseases

184 studies on the registry are indexed under Pancreatic Diseases; 61 are open to participants now.

Browse Pancreatic Diseases studies →

Open to participants now

13 of the 60 studies in Pancreatic Diseases with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Pancreatic Diseases studies recruiting now, 24 (59%) set no upper age limit and 4 (10%) stop at 75 or younger; 6 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Pancreatic Diseases with a site in United States, or all of them as a file.
02

Study summary

This is a randomized trial to compare the standard echoendoscope with the newly developed EndoSound Visual System in the evaluation of lesions in the gastrointestinal tract.

Read the detailed description

Endoscopic ultrasound (EUS) is the gold standard for evaluation and biopsy of lesions in the pancreaticobiliary tract, subepithelial lesions in the gastrointestinal tract and luminal cancer staging due to its high sensitivity and specificity. Endoscopic ultrasound examination is performed by echoendoscopes, which are endoscopes with an ultrasound probe at the distal end to allow endoscopic ultrasound evaluation. A new endoscopic ultrasound system - the EndoSound Visual System has now been developed for endoscopic ultrasound examination. The EndoSound Visual System is a device that can be attached externally to upper gastrointestinal endoscopes, thereby converting a standard endoscope into an echoendoscope which can then be used to perform an EUS examination.

The aim of this randomized trial is to compare the standard echoendoscope with the newly developed EndoSound Visual System in the evaluation of lesions in the gastrointestinal tract.

03

Conditions studied

  • Pancreatic Disease
  • Pancreatic Cancer
  • Pancreatic Cyst
  • Gastrointestinal Tumor
  • Bile Duct Diseases
  • Bile Duct Cancer
  • Lymph Node Disease
  • Submucosal Tumor of Gastrointestinal Tract
  • Gastrointestinal Cancer

Keywords

  • Endoscopic ultrasound
  • EndoSound Vision System
  • Randomized trial
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Any patient undergoing EUS examination for evaluation of the pancreas, bile duct, mediastinal or intraabdominal lymph nodes, or luminal lesions in the esophagus, stomach, duodenum or colon.

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years.
  • Unable to obtain consent for the procedure from either the patient or LAR.
  • Intrauterine pregnancy.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Active comparator
    Standard echoendoscope

    Standard echoendoscope will be used and EUS examination will be performed per standard of care.

    Device: Endoscopic ultrasound examination

  • Active comparator
    EndoSound Vision System

    EndoSound Vision System will be used and EUS examination will be performed per standard of care.

    Device: Endoscopic ultrasound examination

Interventions

  • DeviceEndoscopic ultrasound examination

    Endoscopic ultrasound examination will be performed.

06

What researchers measure

Primary outcomes

  1. Rate of successful completion of the requisite EUS examination

    Rate of successful completion of the requisite examination during EUS between the EndoSound Vision System and standard echoendoscopes will be assessed, compared as a percentage of successfully completed examinations between the standard echoendoscope and Endosound Vision System.

    Time frame: 1 day

Secondary outcomes

  1. Ease of maneuverability of the device

    The ease of maneuverability during EUS between the EndoSound Vision System and standard echoendoscopes will be assessed, based on a rating scale of 1 to 5 (whereby 1 is the most easy to maneuver and 5 is the most difficult to maneuver).

    Time frame: 1 day

  2. Quality of EUS imaging

    The quality of EUS imaging during EUS between the EndoSound Vision System and standard echoendoscopes will be assessed, based on a rating scale of 1 to 5 (whereby 1 is the best quality imaging and 5 is the worst quality imaging).

    Time frame: 1 day

  3. Ease of performing tissue acquisition

    The ease of performing tissue acquisition during EUS between the EndoSound Vision System and standard echoendoscopes will be assessed, based on a rating scale of 1 to 5 (whereby 1 is the most easy to perform and 5 is the most difficult to perform).

    Time frame: 1 day

  4. Diagnostic adequacy of procured specimen on onsite evaluation

    Rate of diagnostic adequacy of procured tissue specimen on onsite evaluation between the EndoSound Vision System and standard echoendoscopes.

    Time frame: 7 days

  5. Diagnostic adequacy of procured specimen in cell block

    Rate of diagnostic adequacy of procured tissue specimen in cell block between the EndoSound Vision System and standard echoendoscopes.

    Time frame: 7 days

  6. Diagnostic accuracy of procured specimen

    Rate of diagnostic accuracy of procured tissue specimen between the EndoSound Vision System and standard echoendoscopes.

    Time frame: 7 days

  7. Procedure duration

    Duration of procedure between the EndoSound Vision System and standard echoendoscopes.

    Time frame: 1 day

  8. Rate of procedure-related adverse events

    Rate of procedure-related adverse events between the EndoSound Vision System and standard echoendoscopes.

    Time frame: 7 days

  9. Procedure costs

    Costs associated with the endoscopic ultrasound procedures between the EndoSound Vision System and standard echoendoscopes.

    Time frame: 7 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

Of 32 interventional studies with no phase under Pancreatic Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 44. This study's planned 14 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start Mar 2024 → Oct 2026, primary completion Dec 2026 → Dec 2027 and completion Dec 2027 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2024
First posted
Apr 1, 2024
StartEst.
Oct 2026was Mar 2024
Primary completionEst.
Dec 2027was Dec 2026
CompletionEst.
Dec 2028was Dec 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 25, 2024→Oct 2026
Oct 20, 2026
Primary completion
Dec 2026→Dec 2027
Oct 20, 2026
Study completion
Dec 2027→Dec 2028
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Start date Mar 25, 2024→Oct 2026
    Primary completion Dec 2026→Dec 2027
    Study completion Dec 2027→Dec 2028
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06340620
Lead sponsor
Orlando Health, Inc.
Responsible party
Sponsor
First posted
Apr 1, 2024
Start date
Oct 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 20, 2026

Study contacts

Ji Young Bang, MD MPH
Contact
jiyoung.bang@orlandohealth.com
321-841-2431
Barbara Broome
Contact
barbara.broome@orlandohealth.com
321-841-4356
Ji Young Bang, MD MPH
principal investigator · Orlando Health, Digestive Health Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion